查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1877391

抗癌藥物市場：依給藥途徑、藥物類別、適應症、通路、劑型、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Anticancer Drug Market, By Route of Administration, By Drug Class, By Indication, By Distribution Channels, By Dosage Form, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 398 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年抗癌藥物市場規模價值 1,666.6956 億美元，從 2025 年到 2032 年將以 9.5% 的複合年成長率成長。

抗癌藥物，也稱為抗腫瘤藥物，是指能夠阻止惡性或癌細胞生長和擴散的藥物。全球癌症發生率的上升以及腫瘤學研究投入的增加是推動市場成長的主要因素，這將促進標靶療法和個人化醫療的發展。然而，抗癌治療的高昂費用和嚴格的法規核准流程限制了中低收入國家獲得這些藥物的機會。儘管如此，免疫療法和精準腫瘤學的發展仍蘊藏著巨大的機遇，它們利用基因譜分析提供更有效、更毒性的治療方案。生物製劑和聯合療法的持續創新預計將在未來幾年推動市場成長。

抗癌藥物市場－市場動態

癌症發生率上升將促進市場成長

全球癌症發生率的上升是抗癌藥物市場成長的主要驅動力之一。人口老化、生活方式的改變、環境污染以及遺傳易感性等因素都導致了全球癌症病例的增加。隨著患者數量的成長，對標靶治療、免疫療法和個人化藥物等有效且先進的治療方案的需求也隨之成長。這種需求的激增促使製藥公司加大研發投入，開發新型療法以改善病患的治療效果。例如，世界衛生組織（WHO）預測，到2040年，全球新增癌症病例將從2018年的1810萬例增至2,940萬例，凸顯了對創新抗癌藥物的迫切需求，並支撐了預測期內市場的持續成長。

抗癌藥物市場細分分析：

全球抗癌藥物市場按給藥途徑、藥物類別、適應症、分銷管道、劑型、最終用戶和地區進行細分。

從劑型來看，抗癌藥物市場可分為固體製劑（片劑、膠囊）、注射劑（預充填式注射器等）、液體製劑及其他劑型。其中，注射劑市場是重要的收入來源，這主要得益於生物製劑和標靶療法的日益普及，這些療法需要透過腸外途徑給藥以提高療效和控制藥物釋放。在腫瘤治療領域，注射劑應用廣泛，因為它們能夠實現精準給藥、快速全身吸收，並在醫療監督下使用時改善治療效果。此外，生物相似藥和注射劑學名藥的日益普及正在擴大藥物的可及性並推動市場擴張。例如，2020年9月，邁蘭公司宣佈在美國推出氟維司群注射液（250毫克/5毫升），這是阿斯特捷利康公司用於治療某些類型晚期乳癌的氟維司群注射液的學名藥，這表明該領域持續的創新和市場活躍度。

根據藥物類別，標靶治療是抗癌藥物市場的重要組成部分，因為它能夠選擇性地攻擊惡性細胞，同時最大限度地減少對健康組織的損傷，從而提高治療效果並降低毒性。這種精準的治療方法直接針對疾病機制，同時最大限度地減少脫靶效應，因此比傳統化療更容易被接受。不斷成長的FDA批准的單株抗體、激酶抑制劑和免疫調節劑產品組合表明癌症研究和開發取得了顯著進展。此外，基因組檢測和伴隨診斷的結合提高了治療的準確性，從而實現了更個人化和有效的癌症治療。越來越多的新型標靶療法獲得監管部門批准，加上強大的在研藥物管線，正在推動該領域的市場潛力。例如，2023年6月，美國FDA批准了達拉非尼和曲美替尼聯合用藥用於治療BRAF V600E突變型癌症的兒童和成人患者，這凸顯了持續的創新和臨床進展正在推動標靶治療領域的成長。

抗癌藥物市場—地域性洞察

抗癌藥物市場呈現出顯著的區域差異，這主要受醫療基礎設施、癌症發生率以及獲得先進療法的機會等因素的影響。亞太地區仍是該市場的主要成長區域，約佔全球市場佔有率的20%。癌症發生率的上升、醫療支出的增加以及現代腫瘤治療手段的普及，都推動了該地區市場的成長。快速的城市化、生活方式的改變以及人口老化也加劇了癌症發生率的上升。中國、印度和日本等國家正大力投資腫瘤研究、臨床試驗和醫療基礎設施建設，以滿足日益成長的癌症治療需求。此外，病患意識的提升、政府的支持性措施以及完善的醫保報銷機制，也促進了標靶藥物、免疫療法和聯合療法等新型療法的應用。

中國抗癌藥物市場—國家概況

中國龐大的人口基數、不斷上升的癌症發生率以及不斷完善的醫療基礎設施，使其成為亞太地區抗癌藥物市場的重要驅動力。世界衛生組織的資料顯示，預計2025年，中國將新增約430萬例癌症病例，其中以肺癌、乳癌和大腸癌最為常見。中國政府正大力投資腫瘤學研究、臨床試驗和醫院網路建設。公眾意識的提高、標靶治療和免疫療法等創新療法的普及以及有利的醫保政策，正在加速先進抗癌藥物的推廣應用，使中國成為該地區佔據主導地位且快速成長的市場。

抗癌藥物市場－競爭格局：

羅氏控股、諾華、百時美施貴寶、輝瑞、默克、阿斯特捷利康和強生是抗癌藥物市場的主要參與者。這些公司憑藉著標靶治療、免疫腫瘤學和精準醫療領域的進步，不斷加劇市場競爭。免疫檢查點抑制劑、CAR-T細胞療法和抗體藥物偶聯物（ADC）的日益普及正在改變治療模式，並推動研發投入。為了加強腫瘤產品線並拓展全球業務，各公司之間進行策略合作、併購活動十分普遍。此外，人工智慧驅動的藥物發現平台與基於生物標記的患者篩選相結合，正在加速創新。為了應對日益嚴重的全球癌症負擔，競爭格局呈現出快速的技術革新、臨床試驗規模的擴大以及對個性化、具成本效益癌症療法的關注等特點。

目錄

第1章：抗癌藥物市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
    • 抗癌藥物市場概況（依給藥途徑分類）
    • 抗癌藥物市場概況（按藥物類別分類）
    • 抗癌藥物市場概況（依適應症分類）
    • 抗癌藥物市場按分銷管道分類的概況
    • 抗癌藥物市場按劑型分類的概況
    • 抗癌藥物市場概況（依終端使用者分類）
    • 各國抗癌藥物市場概況
    • 抗癌藥物市場概況（按地區分類）
  • 競爭洞察

第3章：抗癌藥物市場主要趨勢

  • 抗癌藥物市場促進因素
    • 市場促進因素的影響分析
  • 抗癌藥物市場限制因素
    • 市場限制因素的影響分析
  • 抗癌藥物市場機遇
  • 抗癌藥物市場未來趨勢

第4章：抗癌藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：抗癌藥物市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：抗癌藥物市場概況

  • 2024年抗癌藥物市場佔有率分析
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：抗癌藥物市場－依給藥途徑分類

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 靜脈注射（IV）
    • 皮下
    • 口服
    • 局部/局部

第8章：抗癌藥物市場－依藥物類別分類

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 化療
    • 免疫療法（檢查點抑制劑、CAR-T療法、TCR療法）
    • 單株抗體/生物製劑
    • 荷爾蒙療法
    • 標靶治療
    • 其他（溶瘤病毒、聯合療法、輔助療法）

第9章：抗癌藥物市場－依適應症分類

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 乳癌
    • 肺癌
    • 攝護腺癌
    • 胃腸道癌症
    • 血癌
    • 婦科癌症
    • 其他

第10章：抗癌藥物市場－依分銷管道分類

  • 概述
    • 按分銷管道分類的細分市場佔有率分析
    • 網路藥房
    • 醫院藥房
    • 零售藥房

第11章：抗癌藥物市場－以劑型分類

  • 概述
    • 按劑型分類的細分市場佔有率分析
    • 固體（片劑、膠囊）
    • 注射劑（預充式注射器、其他）
    • 液體
    • 其他

第12章：抗癌藥物市場－以終端使用者分類

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 專科診所
    • 醫院
    • 居家照護
    • 其他

第13章：抗癌藥物市場－依地域分類

  • 介紹
    • 按地域分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗癌藥物主要生產商
    • 北美市場規模及預測（按國家/地區分類）
    • 北美市場規模及預測（依給藥途徑分類）
    • 北美市場規模及預測（按藥物類別分類）
    • 北美市場規模及預測（依適應症分類）
    • 北美市場規模及預測（按分銷管道分類）
    • 北美市場規模及預測（以劑型分類）
    • 北美市場規模及預測（依最終用戶分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗癌藥物主要生產商
    • 歐洲市場規模及預測（按國家/地區分類）
    • 歐洲市場規模及預測（依給藥途徑分類）
    • 歐洲市場規模及預測（按藥物類別分類）
    • 歐洲市場規模及預測（依適應症分類）
    • 歐洲市場規模及預測（依分銷通路分類）
    • 歐洲市場規模及預測（以劑型分類）
    • 歐洲市場規模及預測（依最終用戶分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區
    • 概述
    • 亞太地區抗癌藥物主要生產商
    • 亞太市場規模及預測（依國家/地區分類）
    • 亞太地區市場規模及預測（依給藥途徑分類）
    • 亞太地區市場規模及預測（依藥物類別分類）
    • 亞太地區市場規模及預測（依適應症分類）
    • 亞太地區市場規模及預測（依分銷管道分類）
    • 亞太地區市場規模及預測（依劑型分類）
    • 亞太市場規模及預測（依最終用戶分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗癌藥物主要生產商
    • 拉丁美洲市場規模及預測（按國家/地區分類）
    • 拉丁美洲市場規模及預測（依給藥途徑分類）
    • 拉丁美洲市場規模及預測（按藥物類別分類）
    • 拉丁美洲市場規模及預測（依適應症分類）
    • 拉丁美洲市場規模及預測（按分銷管道分類）
    • 拉丁美洲市場規模及預測（以劑型分類）
    • 拉丁美洲市場規模及預測（按最終用戶分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲抗癌藥物主要生產商
    • 中東和非洲市場規模及預測（按國家/地區分類）
    • 中東和非洲市場規模及預測（按給藥途徑分類）
    • 中東和非洲市場規模及預測（按藥物類別分類）
    • 中東和非洲市場規模及預測（按適應症分類）
    • 中東和非洲市場規模及預測（按分銷管道分類）
    • 中東和非洲市場規模及預測（按劑型分類）
    • 中東和非洲市場規模及預測（按最終用戶分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 中東和非洲其他地區

第14章：主要供應商分析－抗癌藥物產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Novartis
    • Pfizer
    • Merck & Co. (MSD)
    • Bristol Myers Squibb (BMS)
    • AstraZeneca
    • Roche/Genentech
    • Johnson & Johnson/Janssen
    • Sanofi
    • Eli Lilly & Co.
    • Takeda
    • Amgen
    • BeiGene
    • Regeneron
    • Bluebird Bio
    • Seagen
    • Moderna
    • Genmab
    • Incyte
    • Exelixis
    • Hutchmed / Chi-Med
    • Others

第15章：360度分析師視角

第16章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5765

Anticancer Drug Market size was valued at US$ 166,669.56 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.

Anticancer drugs, also known as antineoplastic drugs, are medications that prevent malignant or cancerous cells from growing and spreading. The market is primarily driven by rising global cancer prevalence and increased investments in oncology research, which will result in the development of targeted therapies and personalized medicine. However, the high cost of anticancer treatments and stringent regulatory approval processes limit access in low- and middle-income countries. Nevertheless, significant opportunities exist for the advancement of immunotherapies and precision oncology, which use genetic profiling to provide more effective and less toxic treatment options. Continuous innovation in biologics and combination therapies is expected to drive market growth in the coming years.

Anticancer Drug Market- Market Dynamics

Increasing Prevalence of Cancer to Augment Market Growth

The rising global cancer incidence is one of the primary drivers of the anticancer drug market's growth. Aging populations, changing lifestyles, environmental pollution, and genetic predispositions all contribute to an increase in cancer cases around the world. As the number of patients grows, so does the demand for effective and advanced treatment options such as targeted therapies, immunotherapies, and personalized medicines. This surge is encouraging pharmaceutical companies to increase their R&D investments and develop novel therapeutics to improve patient outcomes. For instance, the World Health Organization (WHO) predicts that the number of new cancer cases will rise from 18.1 million in 2018 to 29.4 million by 2040, highlighting the critical need for innovative anticancer drugs and supporting continued market growth during the forecast period.

Anticancer Drug Market- Segmentation Analysis:

The Global Anticancer Drug Market is segmented on the basis of Route of Administration, Drug Class, Indication, Distribution Channels, Dosage Form, End-Users, and Region.

In terms of Dosage Form, the Anticancer Drug Market is divided into Solid (Tablets, Capsules), Injectable (Prefilled Syringes, Others), Liquid, and Others. Among these, the injectable segment is a significant revenue generator, driven by the growing use of biologics and targeted therapies that require parenteral administration for improved efficacy and controlled release. In oncology, injectables are widely used because they allow for precise dosing, rapid systemic absorption, and improved treatment outcomes when administered under medical supervision. Moreover, the increasing availability of biosimilars and generic injectable formulations is broadening access and driving market expansion. For example, in September 2020, Mylan N.V. announced the U.S. launch of Fulvestrant Injection (250 mg/5 mL), a generic version of AstraZeneca's Faslodex used to treat certain types of advanced breast cancer in women, demonstrating ongoing innovation and market activity in this segment.

Based on drug class, targeted therapy is an important segment of the anticancer drug market due to its ability to selectively attack malignant cells while minimizing damage to healthy tissues, thereby improving treatment efficacy and lowering toxicity. This precision-based approach focuses directly on disease mechanisms while minimizing off-target effects, resulting in higher adoption than conventional chemotherapy. The growing portfolio of FDA-approved monoclonal antibodies, kinase inhibitors, and immune-modulating agents demonstrates significant progress in cancer research and development. Furthermore, the combination of genomic testing and companion diagnostics has increased treatment accuracy, allowing for more personalized and effective cancer care. The growing number of regulatory approvals for novel targeted therapies, combined with a strong pipeline of investigational drugs, is boosting this segment's market potential. For instance, in June 2023, the US FDA approved the combination of dabrafenib and trametinib for pediatric and adult patients with BRAF V600E-mutated cancers, highlighting the ongoing innovation and clinical progress that is driving growth in the targeted therapy segment.

Anticancer Drug Market- Geographical Insights

The Anticancer Drug Market exhibits notable regional diversity, shaped by differences in healthcare infrastructure, cancer prevalence, and access to advanced therapies. Asia-Pacific remains a key growth region for the market, accounting for roughly 20% of the global share. The rising incidence of cancer, increased healthcare expenditure, and expanded access to modern oncology treatments all contribute to growth in this region. Rapid urbanization, lifestyle changes, and an ageing population all contribute to the rise in disease prevalence. Countries such as China, India, and Japan are investing heavily in oncology research, clinical trials, and healthcare infrastructure to meet the rising demand for cancer care. Furthermore, increased patient awareness, supportive government initiatives, and improved reimbursement frameworks are easing the adoption of novel therapies such as targeted drugs, immunotherapies, and combination treatments.

China Anticancer Drug Market- Country Insights

China's large population, rising cancer prevalence, and expanding healthcare infrastructure make it a key driver of the Asia-Pacific anticancer drugs market. According to World Health Organization data, China is expected to see approximately 4.3 million new cancer cases in 2025, with lung, breast, and colorectal cancers being the most common. The government is making substantial investments in oncology research, clinical trials, and hospital networks. Increased awareness, access to innovative therapies such as targeted treatments and immunotherapies, and supportive reimbursement policies are hastening the adoption of advanced anti-cancer drugs, establishing China as a dominant and rapidly growing market in the region.

Anticancer Drug Market- Competitive Landscape:

Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, and Johnson & Johnson are among the anticancer drug market key players. These companies are fueling competition with advances in targeted therapies, immuno-oncology, and precision medicine. The increasing use of checkpoint inhibitors, CAR-T cell therapies, and antibody-drug conjugates (ADCs) is changing treatment paradigms and driving R&D investments. Strategic collaborations, mergers, and acquisitions are common as companies seek to strengthen their oncology pipelines and expand globally. In addition, the combination of AI-powered drug discovery platforms and biomarker-based patient selection is hastening innovation. To address the increasing global cancer burden, the competitive landscape is characterized by rapid technological evolution, clinical trial expansion, and a focus on personalized, cost-effective cancer therapies.

Recent Developments:

In October 2025, AstraZeneca and Daiichi Sankyo announced that Datroway, a precision drug, improved survival rates in patients with advanced breast cancer in a late-stage trial. This development paves the way for more widespread approvals and possible market expansion.

In June 2025, Bristol Myers Squibb signed a $11 billion strategic collaboration agreement with BioNTech. The collaboration entails the co-development and commercialization of BioNTech's investigational bispecific antibody, BNT327, which targets a variety of solid tumor types. BioNTech received an initial payment of $1.5 billion, with non-contingent anniversary payments through 2028 and potential milestone payments of up to $7.6 billion. This collaboration represents a significant investment in the advancement of novel immuno-oncology therapies in the global anticancer drug market, intending to accelerate the development of this bispecific antibody in multiple indications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTICANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis
  • Pfizer
  • Merck & Co. (MSD)
  • Bristol Myers Squibb (BMS)
  • AstraZeneca
  • Roche/Genentech
  • Johnson & Johnson/Janssen
  • Sanofi
  • Eli Lilly & Co.
  • Takeda
  • Amgen
  • BeiGene
  • Regeneron
  • Bluebird Bio
  • Seagen
  • Moderna
  • Genmab
  • Incyte
  • Exelixis
  • Hutchmed / Chi-Med
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Subcutaneous
  • Oral
  • Topical / Localized

GLOBAL ANTICANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
  • Monoclonal Antibodies / Biologics
  • Hormone Therapy
  • Targeted Therapy
  • Others (Oncolytic viruses, combination therapies, adjuncts)

GLOBAL ANTICANCER DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Blood Cancer
  • Gynaecologic Cancer
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY DISTRIBUTION CHANNELS- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

GLOBAL ANTICANCER DRUG MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Solid (Tablets, Capsule)
  • Injectable (Prefilled Syringes, Others)
  • Liquid
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Specialty Clinics
  • Hospitals
  • Homecare
  • Others

GLOBAL ANTICANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Anticancer Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Anticancer Drug Market Snippet by Route of Administration
    • 2.1.2. Anticancer Drug Market Snippet by Drug Class
    • 2.1.3. Anticancer Drug Market Snippet by Indication
    • 2.1.4. Anticancer Drug Market Snippet by Distribution Channels
    • 2.1.5. Anticancer Drug Market Snippet by Dosage Form
    • 2.1.6. Anticancer Drug Market Snippet by End-Users
    • 2.1.7. Anticancer Drug Market Snippet by Country
    • 2.1.8. Anticancer Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Anticancer Drug Key Market Trends

  • 3.1. Anticancer Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Anticancer Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Anticancer Drug Market Opportunities
  • 3.4. Anticancer Drug Market Future Trends

4. Anticancer Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Anticancer Drug Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Anticancer Drug Market Landscape

  • 6.1. Anticancer Drug Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Anticancer Drug Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 7.1.2. Intravenous (IV)
    • 7.1.3. Subcutaneous
    • 7.1.4. Oral
    • 7.1.5. Topical / Localized

8. Anticancer Drug Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
    • 8.1.4. Monoclonal Antibodies / Biologics
    • 8.1.5. Hormone Therapy
    • 8.1.6. Targeted Therapy
    • 8.1.7. Others (Oncolytic viruses, combination therapies, adjuncts)

9. Anticancer Drug Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 9.1.2. Breast Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Prostate Cancer
    • 9.1.5. Gastrointestinal Cancer
    • 9.1.6. Blood Cancer
    • 9.1.7. Gynaecologic Cancer
    • 9.1.8. Others

10. Anticancer Drug Market - By Distribution Channels

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channels, 2024 & 2032 (%)
    • 10.1.2. Online Pharmacy
    • 10.1.3. Hospital Pharmacy
    • 10.1.4. Retail Pharmacy

11. Anticancer Drug Market - By Dosage Form

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 11.1.2. Solid (Tablets, Capsule)
    • 11.1.3. Injectable (Prefilled Syringes, Others)
    • 11.1.4. Liquid
    • 11.1.5. Others

12. Anticancer Drug Market - By End-Users

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 12.1.2. Specialty Clinics
    • 12.1.3. Hospitals
    • 12.1.4. Homecare
    • 12.1.5. Others

13. Anticancer Drug Market- By Geography

  • 13.1. Introduction
    • 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 13.2. North America
    • 13.2.1. Overview
    • 13.2.2. Anticancer Drug Key Manufacturers in North America
    • 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.2.7. North America Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.2.8. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.2.9. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.2.10. U.S.
      • 13.2.10.1. Overview
      • 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.10.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.2.10.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.2.10.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.2.10.6. U.S. Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.2.10.7. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.2.10.8. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.2.11. Canada
      • 13.2.11.1. Overview
      • 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.11.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.2.11.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.2.11.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.2.11.6. Canada Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.2.11.7. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.2.11.8. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.3. Europe
    • 13.3.1. Overview
    • 13.3.2. Anticancer Drug Key Manufacturers in Europe
    • 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.3.7. Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.3.8. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.3.9. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.10. Germany
      • 13.3.10.1. Overview
      • 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.10.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.10.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.10.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.10.6. Germany Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.10.7. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.10.8. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.11. UK
      • 13.3.11.1. Overview
      • 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.11.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.11.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.11.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.11.6. UK Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.11.7. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.11.8. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.12. France
      • 13.3.12.1. Overview
      • 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.12.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.12.6. France Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.12.7. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.12.8. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.13. Italy
      • 13.3.13.1. Overview
      • 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.13.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.13.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.13.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.13.6. Italy Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.13.7. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.13.8. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.14. Spain
      • 13.3.14.1. Overview
      • 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.14.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.14.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.14.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.14.6. Spain Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.14.7. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.14.8. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.15. The Netherlands
      • 13.3.15.1. Overview
      • 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.15.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.15.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.15.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.15.6. The Netherlands Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.15.7. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.15.8. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.16. Sweden
      • 13.3.16.1. Overview
      • 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.16.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.16.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.16.6. Sweden Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.16.7. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.16.8. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.17. Russia
      • 13.3.17.1. Overview
      • 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.17.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.17.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.17.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.17.6. Russia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.17.7. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.17.8. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.18. Poland
      • 13.3.18.1. Overview
      • 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.18.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.18.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.18.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.18.6. Poland Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.18.7. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.18.8. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.3.19. Rest of Europe
      • 13.3.19.1. Overview
      • 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.19.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.3.19.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.3.19.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.3.19.6. Rest of the Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.3.19.7. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.3.19.8. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.4. Asia Pacific (APAC)
    • 13.4.1. Overview
    • 13.4.2. Anticancer Drug Key Manufacturers in Asia Pacific
    • 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.4.7. APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.4.8. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.4.9. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.10. China
      • 13.4.10.1. Overview
      • 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.10.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.10.6. China Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.10.7. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.10.8. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.11. India
      • 13.4.11.1. Overview
      • 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.11.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.11.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.11.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.11.6. India Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.11.7. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.11.8. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.12. Japan
      • 13.4.12.1. Overview
      • 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.12.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.12.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.12.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.12.6. Japan Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.12.7. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.12.8. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.13. South Korea
      • 13.4.13.1. Overview
      • 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.13.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.13.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.13.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.13.6. South Korea Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.13.7. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.13.8. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.14. Australia
      • 13.4.14.1. Overview
      • 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.14.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.14.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.14.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.14.6. Australia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.14.7. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.14.8. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.15. Indonesia
      • 13.4.15.1. Overview
      • 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.15.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.15.6. Indonesia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.15.7. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.15.8. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.16. Thailand
      • 13.4.16.1. Overview
      • 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.16.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.16.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.16.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.16.6. Thailand Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.16.7. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.16.8. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.17. Philippines
      • 13.4.17.1. Overview
      • 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.17.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.17.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.17.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.17.6. Philippines Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.17.7. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.17.8. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.4.18. Rest of APAC
      • 13.4.18.1. Overview
      • 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.18.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.4.18.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.4.18.7. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.4.18.8. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.5. Latin America (LATAM)
    • 13.5.1. Overview
    • 13.5.2. Anticancer Drug Key Manufacturers in Latin America
    • 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.5.7. LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.5.8. LATAM Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.5.9. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.10. Brazil
      • 13.5.10.1. Overview
      • 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.10.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.10.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.10.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.10.6. Brazil Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.10.7. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.10.8. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.11. Mexico
      • 13.5.11.1. Overview
      • 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.11.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.11.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.11.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.11.6. Mexico Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.11.7. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.11.8. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.12. Argentina
      • 13.5.12.1. Overview
      • 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.12.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.12.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.12.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.12.6. Argentina Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.12.7. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.12.8. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.13. Colombia
      • 13.5.13.1. Overview
      • 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.13.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.13.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.13.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.13.6. Colombia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.13.7. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.13.8. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.5.14. Rest of LATAM
      • 13.5.14.1. Overview
      • 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.14.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.5.14.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.5.14.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.5.14.6. Rest of LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.5.14.7. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.5.14.8. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
  • 13.6. Middle East and Africa
    • 13.6.1. Overview
    • 13.6.2. Anticancer Drug Key Manufacturers in Middle East and Africa
    • 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 13.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 13.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
    • 13.6.8. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 13.6.9. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.10. Saudi Arabia
      • 13.6.10.1. Overview
      • 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.10.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.10.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.10.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.10.6. Saudi Arabia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.10.7. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.10.8. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.11. United Arab Emirates
      • 13.6.11.1. Overview
      • 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.11.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.11.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.11.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.11.6. United Arab Emirates Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.11.7. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.11.8. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.12. Israel
      • 13.6.12.1. Overview
      • 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.12.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.12.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.12.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.12.6. Israel Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.12.7. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.12.8. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.13. Turkey
      • 13.6.13.1. Overview
      • 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.13.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.13.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.13.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.13.6. Turkey Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.13.7. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.13.8. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.14. Algeria
      • 13.6.14.1. Overview
      • 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.14.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.14.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.14.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.14.6. Algeria Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.14.7. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.14.8. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.15. Egypt
      • 13.6.15.1. Overview
      • 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.15.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.15.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.15.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.15.6. Egypt Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.15.7. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.15.8. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 13.6.16. Rest of MEA
      • 13.6.16.1. Overview
      • 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.16.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 13.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 13.6.16.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 13.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
      • 13.6.16.7. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 13.6.16.8. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Anticancer Drug Industry

  • 14.1. Competitive Benchmarking
    • 14.1.1. Competitive Dashboard
    • 14.1.2. Competitive Positioning
  • 14.2. Company Profiles
    • 14.2.1. Novartis
    • 14.2.2. Pfizer
    • 14.2.3. Merck & Co. (MSD)
    • 14.2.4. Bristol Myers Squibb (BMS)
    • 14.2.5. AstraZeneca
    • 14.2.6. Roche/Genentech
    • 14.2.7. Johnson & Johnson/Janssen
    • 14.2.8. Sanofi
    • 14.2.9. Eli Lilly & Co.
    • 14.2.10. Takeda
    • 14.2.11. Amgen
    • 14.2.12. BeiGene
    • 14.2.13. Regeneron
    • 14.2.14. Bluebird Bio
    • 14.2.15. Seagen
    • 14.2.16. Moderna
    • 14.2.17. Genmab
    • 14.2.18. Incyte
    • 14.2.19. Exelixis
    • 14.2.20. Hutchmed / Chi-Med
    • 14.2.21. Others

15. 360 Degree Analyst View

16. Appendix

  • 16.1. Research Methodology
  • 16.2. References
  • 16.3. Abbreviations
  • 16.4. Disclaimer
  • 16.5. Contact Us